Cidara Therapeutics (CDTX) CFO cashes out shares in Merck buyout at $221.50 each
Rhea-AI Filing Summary
Cidara Therapeutics Chief Financial Officer Frank Karbe reported the cash-out of his equity holdings in connection with Merck’s acquisition of the company. On January 7, 2026, he disposed of 7,526 shares of Cidara common stock at $221.50 per share in the tender offer and merger, and a further 43,125 shares were reduced to zero balance as they were converted into the right to receive cash.
The filing also shows 115,000 employee stock options were cancelled on January 7, 2026 and converted into cash based on the spread between the $221.50 merger price and their exercise price. Under the Merger Agreement, all outstanding common shares were exchanged for $221.50 per share and all Series A preferred shares for $15,505.00 per share in cash, and Cidara became a wholly owned subsidiary of Merck.
Positive
- None.
Negative
- None.
Insights
Cidara’s CFO equity is fully cashed out as Merck closes its acquisition.
The disclosure shows how the Merck transaction monetized Cidara Therapeutics equity awards for its Chief Financial Officer. On January 7, 2026, 7,526 common shares were disposed of at $221.50 per share, with an additional 43,125 shares converted so that the post-transaction common stock balance is zero. This aligns with the merger structure where all public equity is taken out for cash.
On the derivative side, 115,000 employee stock options were first made fully vested and exercisable and then cancelled at the merger effective time. The cash payment for each option equals the number of underlying shares multiplied by the excess of the $221.50 merger price over the option’s exercise price, as described in the footnotes. The same mechanics apply to restricted stock units, which were converted into cash at $221.50 per underlying share, standardizing treatment across equity incentives.
Strategically, this filing documents the clean transition from a publicly traded structure to a wholly owned subsidiary of Merck Sharp & Dohme LLC. All outstanding common shares and Series A preferred shares were converted into fixed cash amounts of $221.50 and $15,505.00, respectively, while tendered and treasury shares were excluded as stated. Future company disclosures, if any, will occur under Merck’s ownership rather than as a standalone listed issuer.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Disposition | Employee Stock Option (right to buy) | 115,000 | $0.00 | -- |
| Disposition | Common Stock | 7,526 | $221.50 | $1.67M |
| Disposition | Common Stock | 43,125 | $0.00 | -- |
Footnotes (1)
- Pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated November 13, 2025, by and among Cidara Therapeutics, Inc. (the "Issuer"), Merck Sharp & Dohme LLC ("Merck") and Caymus Purchaser, Inc., a wholly owned subsidiary of Merck ("Purchaser"), on January 7, 2026, Purchaser completed a tender offer to acquire (i) all outstanding shares of common stock of the Issuer, par value $0.0001 per share (each, a "Common Share") and (ii) all outstanding shares of Series A Convertible Voting Preferred Stock of the Issuer, par value $0.0001 per share (each, a "Series A Share"), and thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Merck (the "Merger"). [continues to Footnote 2] [continues from Footnote 1] Pursuant to the terms of the Merger Agreement, Common Shares and Series A Shares were tendered and disposed of at the Offer Acceptance Time (as defined in the Merger Agreement) in exchange for the right to receive (i) $221.50 per Common Share (the "Common Share Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes, and (ii) $15,505.00 per Series A Share (the "Series A Merger Consideration"), in cash, without interest, subject to any applicable withholding of taxes. [continues to Footnote 3] [continues from Footnote 2] At the effective time of the Merger, each issued and outstanding Common Share and Series A Share (other than Common Shares (a) held by the Issuer (or in the Issuer's treasury), Merck, Purchaser, any other direct or indirect wholly owned subsidiary of Merck or the Issuer, or by stockholders of the Issuer who have properly exercised and perfected their statutory rights of appraisal, or (b) irrevocably accepted for purchase in the tender offer) was automatically canceled and converted into the right to receive the Common Share Merger Consideration and the Series A Merger Consideration, respectively, without interest and subject to any applicable withholding of taxes. Includes 89 shares acquired pursuant to the Issuer's Employee Stock Purchase Plan (ESPP) on December 18, 2025. As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding restricted stock unit award ("RSU"), whether vested or unvested, was cancelled and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to (i) the total number of Common Shares issuable in settlement of such RSU immediately prior to the effective time of the Merger multiplied by (ii) $221.50 per Common Share. As of immediately prior to and contingent upon the occurrence of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option became fully vested and exercisable, and to the extent outstanding and unexercised as of immediately before the effective time of the Merger, was cancelled at the effective time of the Merger and converted into the right to receive cash, without interest, subject to any applicable withholding of taxes, in an amount equal to the product of (i) the total number of Common Shares subject to such option immediately prior to the effective time of the Merger multiplied by (ii) the excess of (x) $221.50 per Common Share over (y) the exercise price payable per Common Share under such option.
